1
|
Simard JC, Thibodeau JF, Leduc M, Tremblay M, Laverdure A, Sarra-Bournet F, Gagnon W, Ouboudinar J, Gervais L, Felton A, Letourneau S, Geerts L, Cloutier MP, Hince K, Corpuz R, Blais A, Quintela VM, Duceppe JS, Abbott SD, Blais A, Zacharie B, Laurin P, Laplante SR, Kennedy CRJ, Hébert RL, Leblond FA, Grouix B, Gagnon L. Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease. Sci Rep 2020; 10:12778. [PMID: 32728158 PMCID: PMC7391726 DOI: 10.1038/s41598-020-69675-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Accepted: 07/14/2020] [Indexed: 12/11/2022] Open
Abstract
Non-alcoholic Fatty Liver Disease (NAFLD) is the most common form of liver disease and is associated with metabolic dysregulation. Although G protein-coupled receptor 84 (GPR84) has been associated with inflammation, its role in metabolic regulation remains elusive. The aim of our study was to evaluate the potential of PBI-4547 for the treatment of NAFLD and to validate the role of its main target receptor, GPR84. We report that PBI-4547 is a fatty acid mimetic, acting concomitantly as a GPR84 antagonist and GPR40/GPR120 agonist. In a mouse model of diet-induced obesity, PBI-4547 treatment improved metabolic dysregulation, reduced hepatic steatosis, ballooning and NAFLD score. PBI-4547 stimulated fatty acid oxidation and induced gene expression of mitochondrial uncoupling proteins in the liver. Liver metabolomics revealed that PBI-4547 improved metabolic dysregulation induced by a high-fat diet regimen. In Gpr84−/− mice, PBI-4547 treatment failed to improve various key NAFLD-associated parameters, as was observed in wildtype littermates. Taken together, these results highlight a detrimental role for the GPR84 receptor in the context of meta-inflammation and suggest that GPR84 antagonism via PBI-4547 may reflect a novel treatment approach for NAFLD and its related complications.
Collapse
Affiliation(s)
- Jean-Christophe Simard
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Jean-François Thibodeau
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada. .,Department of Cellular and Molecular Medicine, Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, 451 Smyth Road, Ottawa, ON, K1H 8M5, Canada.
| | - Martin Leduc
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Mikael Tremblay
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Alexandre Laverdure
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - François Sarra-Bournet
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - William Gagnon
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Jugurtha Ouboudinar
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Liette Gervais
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Alexandra Felton
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Sylvie Letourneau
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Lilianne Geerts
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Marie-Pier Cloutier
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Kathy Hince
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Ramon Corpuz
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Alexandra Blais
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Vanessa Marques Quintela
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Jean-Simon Duceppe
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Shaun D Abbott
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Amélie Blais
- Department of Cellular and Molecular Medicine, Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, 451 Smyth Road, Ottawa, ON, K1H 8M5, Canada
| | - Boulos Zacharie
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Pierre Laurin
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Steven R Laplante
- Institut National de La Recherche Scientifique, Institut Armand-Frappier, 531 Boul. Des Prairies, Laval, QC, H7V 5B7, Canada
| | - Christopher R J Kennedy
- Department of Cellular and Molecular Medicine, Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, 451 Smyth Road, Ottawa, ON, K1H 8M5, Canada
| | - Richard L Hébert
- Department of Cellular and Molecular Medicine, Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, 451 Smyth Road, Ottawa, ON, K1H 8M5, Canada
| | - François A Leblond
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Brigitte Grouix
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| | - Lyne Gagnon
- Liminal R&D Biosciences Inc., 500 Boulevard Cartier Ouest (Suite 150), Laval, QC, H7V 5B7, Canada
| |
Collapse
|
2
|
Affiliation(s)
- Mylène de Léséleuc
- Prometic Biosciences Inc.; 500 boul. Cartier Ouest, Bureau 150 H7V 5B7 Laval Québec Canada
| | - Andrew Kukor
- Prometic Biosciences Inc.; 500 boul. Cartier Ouest, Bureau 150 H7V 5B7 Laval Québec Canada
| | - Shaun D. Abbott
- Prometic Biosciences Inc.; 500 boul. Cartier Ouest, Bureau 150 H7V 5B7 Laval Québec Canada
| | - Boulos Zacharie
- Prometic Biosciences Inc.; 500 boul. Cartier Ouest, Bureau 150 H7V 5B7 Laval Québec Canada
| |
Collapse
|
3
|
Zacharie B, Abbott SD, Baigent CB, Doyle C, Yalagala RS. An Efficient Two-Step Preparation of α-, β-, γ- or δ-Amino Acids from 2-Pyrazinones, 2-Hydroxypyrimidines or 2-Pyridones Respectively. European J Org Chem 2018. [DOI: 10.1002/ejoc.201801134] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Boulos Zacharie
- Prometic Biosciences Inc.; 500 boul. Cartier Ouest, Bureau 150 H7V 5B7 Laval Québec Canada
| | - Shaun D. Abbott
- Prometic Biosciences Inc.; 500 boul. Cartier Ouest, Bureau 150 H7V 5B7 Laval Québec Canada
| | - Christopher B. Baigent
- Prometic Biosciences Inc.; 500 boul. Cartier Ouest, Bureau 150 H7V 5B7 Laval Québec Canada
| | - Christopher Doyle
- Prometic Biosciences Inc.; 500 boul. Cartier Ouest, Bureau 150 H7V 5B7 Laval Québec Canada
| | - Ravi Shekar Yalagala
- Prometic Biosciences Inc.; 500 boul. Cartier Ouest, Bureau 150 H7V 5B7 Laval Québec Canada
| |
Collapse
|
4
|
Zacharie B, Abbott SD, Duceppe J, Gagnon L, Grouix B, Geerts L, Gervais L, Sarra‐Bournet F, Perron V, Wilb N, Penney CL, Laurin P. Design and Synthesis of New 1,3,5-Trisubstituted Triazines for the Treatment of Cancer and Inflammation. ChemistryOpen 2018; 7:737-749. [PMID: 30258746 PMCID: PMC6148406 DOI: 10.1002/open.201800136] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Indexed: 01/08/2023] Open
Abstract
Low-molecular-weight synthetic molecules 1 with the general 2-(fluorophenylamino)-4,6-disubstituted 1,3,5-triazine structure and showing anti-inflammatory and anticancer activities were explored. Structure-activity relationship studies demonstrated the importance of the aminopentyl chain, the 3- or 4-fluorophenylaniline component, and the presence of at least one substituent, such as a tyramine moiety, attached directly to the triazine ring as essential for good activity. These compounds, represented by leads 4-{2-[4-(5-Aminopentylamino)-6-(3-fluorophenylamino)-1,3,5-triazin-2-ylamino]ethyl}phenol (6) and 4-{2-[4-(5-Aminopentylamino)-6-(4-fluorophenylamino)-1,3,5-triazin-2-ylamino]ethyl}phenol (10), displayed moderate and significant in vitro and in vivo dual activities, respectively, and address the molecular link between inflammation and cancer. Compound 10 demonstrated significant antitumor efficacy upon administration by the oral and intravenous routes in several animal models. This class of triazine compounds is new, safe, and nontoxic and offers a novel approach to the treatment of inflammation and cancer.
Collapse
Affiliation(s)
- Boulos Zacharie
- Prometic Biosciences Inc.500 boul. Cartier Ouest, Bureau 150LavalQuébecH7V 5B7Canada
| | - Shaun D. Abbott
- Prometic Biosciences Inc.500 boul. Cartier Ouest, Bureau 150LavalQuébecH7V 5B7Canada
| | - Jean‐Simon Duceppe
- Prometic Biosciences Inc.500 boul. Cartier Ouest, Bureau 150LavalQuébecH7V 5B7Canada
| | - Lyne Gagnon
- Prometic Biosciences Inc.500 boul. Cartier Ouest, Bureau 150LavalQuébecH7V 5B7Canada
| | - Brigitte Grouix
- Prometic Biosciences Inc.500 boul. Cartier Ouest, Bureau 150LavalQuébecH7V 5B7Canada
| | - Lilianne Geerts
- Prometic Biosciences Inc.500 boul. Cartier Ouest, Bureau 150LavalQuébecH7V 5B7Canada
| | - Liette Gervais
- Prometic Biosciences Inc.500 boul. Cartier Ouest, Bureau 150LavalQuébecH7V 5B7Canada
| | | | - Valérie Perron
- Prometic Biosciences Inc.500 boul. Cartier Ouest, Bureau 150LavalQuébecH7V 5B7Canada
| | - Nicole Wilb
- Prometic Biosciences Inc.500 boul. Cartier Ouest, Bureau 150LavalQuébecH7V 5B7Canada
| | - Christopher L. Penney
- Prometic Biosciences Inc.500 boul. Cartier Ouest, Bureau 150LavalQuébecH7V 5B7Canada
| | - Pierre Laurin
- Prometic Biosciences Inc.500 boul. Cartier Ouest, Bureau 150LavalQuébecH7V 5B7Canada
| |
Collapse
|
5
|
Grouix B, Hince K, Sarra-Bournet F, Felton A, Tremblay M, Cloutier MP, Abbott S, Duceppe JS, Zacharie B, Laurin P, Gagnon L. SP047ORAL TREATMENT WITH PBI-4547, A NOVEL FIRST-IN-CLASS ANTI-DIABETIC AND ANTI-FIBROTIC COMPOUND, IMPROVES GLOMERULAR FUNCTION AND PREVENTS PODOCYTE INJURY IN THE DIABETIC DB/DB MOUSE MODEL. Nephrol Dial Transplant 2015. [DOI: 10.1093/ndt/gfv188.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Kanlaya R, Sintiprungrat K, Thongboonkerd V, Torremade N, Bindels R, Hoenderop J, Fernandez E, Dusso A, Valdivielso JM, Krueger T, Boor P, Schafer C, Westenfeld R, Brandenburg V, Schlieper G, Jahnen-Dechent W, Ketteler M, Jee W, Li X, Richards B, Floege J, Goncalves JG, Canale D, de Braganca AC, Shimizu MHM, Moyses RMA, Andrade L, Seguro AC, Volpini RA, Romoli S, Migliorini A, Anders HJ, Eskova O, Neprintseva N, Tchebotareva N, Bobkova I, Kozlovskaya L, Simic I, Tabatabaeifar M, Wlodkowski T, Denc H, Mollet G, Antignac C, Schaefer F, Ekaterina IA, Giardino L, Rastaldi MP, Van den Heuvel L, Levtchenko E, Okina C, Okamoto T, Kamata M, Murano J, Kobayashi K, Takeuchi K, Kamata F, Sakai T, Naito S, Aoyama T, Sano T, Takeuchi Y, Kamata K, Thomasova D, Bruns HA, Liapis H, Anders HJ, Iwashita T, Hasegawa H, Takayanagi K, Shimizu T, Asakura J, Okazaki S, Kogure Y, Hatano M, Hara H, Inamura M, Iwanaga M, Mitani T, Mitarai T, Savin VJ, Sharma M, Wei C, Reiser J, McCarthy ET, Sharma R, Gauchat JF, Eneman B, Freson K, Van den Heuvel L, Van Geet C, Levtchenko E, Choi DE, Jeong JY, Chang YK, Na KR, Lee KW, Shin YT, Ni HF, Chen JF, Zhang MH, Pan MM, Liu BC, Lee KW, Jeong JY, Choi DE, Chang YK, Kim SS, Na KR, Shin YT, Suzuki T, Iyoda M, Matsumoto K, Shindo-Hirai Y, Kuno Y, Wada Y, Yamamoto Y, Shibata T, Akizawa T, Munoz-Felix JM, Lopez-Novoa JM, Martinez-Salgado C, Ehling J, Babickova J, Gremse F, Kiessling F, Floege J, Lammers T, Boor P, Lech M, Gunthner R, Lorenz G, Ryu M, Grobmayr R, Susanti H, Kobayashi KS, Flavell RA, Anders HJ, Rayego-Mateos S, Morgado J, Sanz AB, Eguchi S, Pato J, Keri G, Egido J, Ortiz A, Ruiz-Ortega M, Leduc M, Geerts L, Grouix B, Sarra-Bournet F, Felton A, Gervais L, Abbott S, Duceppe JS, Zacharie B, Penney C, Laurin P, Gagnon L, Detsika MG, Duann P, Lianos EA, Leong KI, Chiang CK, Yang CC, Wu CT, Chen LP, Hung KY, Liu SH, Carvalho FF, Teixeira VP, Almeida WS, Schor N, Small DM, Bennett NC, Coombes J, Johnson DW, Gobe GC, Montero N, Prada A, Riera M, Orfila M, Pascual J, Rodriguez E, Barrios C, Kokeny G, Fazekas K, Rosivall L, Mozes MM, Munoz-Felix JM, Lopez-Novoa JM, Martinez-Salgado C, Hornigold N, Hughes J, Mooney A, Benardeau A, Riboulet W, Vandjour A, Jacobsen B, Apfel C, Conde-Knape K, Grouix B, Felton A, Sarra-Bournet F, Leduc M, Geerts L, Gervais L, Abbott S, Bienvenu JF, Duceppe JS, Zacharie B, Penney C, Laurin P, Gagnon L, Tanaka T, Yamaguchi J, Nangaku M, Niwa T, Bolati D, Shimizu H, Yisireyili M, Nishijima F, Brocca A, Virzi G, de Cal M, Ronco C, Priante G, Musacchio E, Valvason C, Sartori L, Piccoli A, Baggio B, Boor P, Perkuhn M, Weibrecht M, Zok S, Martin IV, Schoth F, Ostendorf T, Kuhl C, Floege J, Karabaeva A, Essaian A, Beresneva O, Parastaeva M, Kayukov I, Smirnov A, Audzeyenka I, Kasztan M, Piwkowska A, Rogacka D, Angielski S, Jankowski M, Bockmeyer CL, Kokowicz K, Agustian PA, Zell S, Wittig J, Becker JU, Nishizono R, Venkatareddy MP, Chowdhury MA, Wang SQ, Fukuda A, Wickman LT, Yang Y, Wiggins RC, Fazio MR, Donato V, Lucisano S, Cernaro V, Lupica R, Trimboli D, Montalto G, Aloisi C, Mazzeo AT, Buemi M, Gawrys O, Olszynski KH, Kuczeriszka M, Gawarecka K, Swiezewska E, Chmielewski M, Masnyk M, Rafalowska J, Kompanowska-Jezierska E, Lee WC, Chau YY, Lee LC, Chiu CH, Lee CT, Chen JB, Kim WK, Shin SJ. Experimental models of CKD. Nephrol Dial Transplant 2013. [DOI: 10.1093/ndt/gft114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
7
|
Perry G, Choudhary M, Lopez Rodriguez M, Kalasz H, Bernard M, Barlocco D, Zacharie B, Kenneth S, Hwu J. Editorial [Special Issue in Honor of the 70th Birthday of Dr. Atta-ur-Rahman, FRS]. Mini Rev Med Chem 2012. [DOI: 10.2174/138955712802762347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
8
|
Zacharie B, Abbott S, Cloutier J, Houde K, Penney C. A Facile Synthesis of 6H-[1,3,5]Triazino[2,1-b]quinazolin-6-ones. SYNTHESIS-STUTTGART 2011. [DOI: 10.1055/s-0030-1260047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Zacharie B, Abbott SD, Bienvenu JF, Cameron AD, Cloutier J, Duceppe JS, Ezzitouni A, Fortin D, Houde K, Lauzon C, Moreau N, Perron V, Wilb N, Asselin M, Doucet A, Fafard ME, Gaudreau D, Grouix B, Sarra-Bournet F, St-Amant N, Gagnon L, Penney CL. 2,4,6-trisubstituted triazines as protein a mimetics for the treatment of autoimmune diseases. J Med Chem 2010; 53:1138-45. [PMID: 20047277 DOI: 10.1021/jm901403r] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A first-in-class series of low molecular weight trisubstituted triazines were synthesized and evaluated for their ability to mimic protein A binding to human IgG antibody. The structure-activity relationship (SAR) demonstrates that the 1,3-phenylenediamine component was essential for robust activity. Twenty-two compounds, represented by lead molecule 34, displayed significant activity compared to protein A. These compounds may prove useful for the treatment of autoimmune disease.
Collapse
Affiliation(s)
- Boulos Zacharie
- ProMetic BioSciences Inc., 500 Boulevard Cartier Ouest, Bureau 150, Laval, Québec H7V 5B7, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Duceppe JS, Perron V, Cloutier J, Penney C, Zacharie B. An Efficient Kilogram-Scale Synthesis of N, N′-Bis(4,6-disubstituted 1,3,5-triazin-2-yl)-4-aminophenetylamine. Org Process Res Dev 2009. [DOI: 10.1021/op900202b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jean-Simon Duceppe
- ProMetic BioSciences Inc., 500 boulevard Cartier Ouest, Bureau 150, Laval, Québec, Canada H7V 5B7
| | - Valérie Perron
- ProMetic BioSciences Inc., 500 boulevard Cartier Ouest, Bureau 150, Laval, Québec, Canada H7V 5B7
| | - Josée Cloutier
- ProMetic BioSciences Inc., 500 boulevard Cartier Ouest, Bureau 150, Laval, Québec, Canada H7V 5B7
| | - Christopher Penney
- ProMetic BioSciences Inc., 500 boulevard Cartier Ouest, Bureau 150, Laval, Québec, Canada H7V 5B7
| | - Boulos Zacharie
- ProMetic BioSciences Inc., 500 boulevard Cartier Ouest, Bureau 150, Laval, Québec, Canada H7V 5B7
| |
Collapse
|
11
|
Zacharie B, Ezzitouni A, Duceppe JS, Penney C. A Simple and Efficient Large-Scale Synthesis of Metal Salts of Medium-Chain Fatty Acids. Org Process Res Dev 2009. [DOI: 10.1021/op900038v] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Boulos Zacharie
- ProMetic BioSciences Inc., 500 Boulevard Cartier Ouest, Bureau 150, Laval, Québec, Canada H7V 5B7
| | - Abdallah Ezzitouni
- ProMetic BioSciences Inc., 500 Boulevard Cartier Ouest, Bureau 150, Laval, Québec, Canada H7V 5B7
| | - Jean-Simon Duceppe
- ProMetic BioSciences Inc., 500 Boulevard Cartier Ouest, Bureau 150, Laval, Québec, Canada H7V 5B7
| | - Christopher Penney
- ProMetic BioSciences Inc., 500 Boulevard Cartier Ouest, Bureau 150, Laval, Québec, Canada H7V 5B7
| |
Collapse
|
12
|
Zacharie B, Perron V, Abbott S, Moreau N, Lee D, Penney C. A Method for the Selective Protection of Aromatic Amines in the Presence of Aliphatic Amines. SYNTHESIS-STUTTGART 2008. [DOI: 10.1055/s-0028-1083290] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Zacharie B, Fortin D, Wilb N, Bienvenu JF, Asselin M, Grouix B, Penney C. 2,6,9-Trisubstituted purine derivatives as protein A mimetics for the treatment of autoimmune diseases. Bioorg Med Chem Lett 2008; 19:242-6. [PMID: 19010675 DOI: 10.1016/j.bmcl.2008.10.116] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2008] [Revised: 10/17/2008] [Accepted: 10/20/2008] [Indexed: 11/26/2022]
Abstract
A series of 9-substituted and 2,9-disubstituted 6-(3-aminophenylamino) purines were synthesized and evaluated for their ability to mimic protein A binding to human IgG antibody. The structure-activity relationship (SAR) demonstrates that the 6-(3-aminoanilinyl) purine component was essential for activity. Purine 14 demonstrated significant activity, compared to protein A. These compounds may prove useful for the treatment of autoimmune diseases.
Collapse
|
14
|
Allam M, Julien N, Zacharie B, Penney C, Gagnon L. Enhancement of Th1 type cytokine production and primary T cell activation by PBI-1393. Clin Immunol 2007; 125:318-27. [PMID: 17827067 DOI: 10.1016/j.clim.2007.07.017] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2007] [Revised: 07/26/2007] [Accepted: 07/27/2007] [Indexed: 11/15/2022]
Abstract
In previous reports, we have shown that PBI-1393 (formerly BCH-1393), N,N-Dimethylaminopurine pentoxycarbonyl D-arginine, stimulates cytotoxic T-lymphocyte (CTL) responses both in vitro and in vivo in normal immune status and immunosuppressed mice. Additionally, PBI-1393 was tested for anticancer activity in syngeneic mouse experimental tumor models and it displayed significant inhibition of tumor outgrowths when given in combination with sub-therapeutic doses of cytotoxic drugs (cyclophosphamide, 5-fluorouracil, doxorubicin and cis-platinum). However, the mechanism of action of PBI-1393 was still unknown. Here, we report that PBI-1393 enhances IL-2 and IFN-gamma production in human activated T cells by 51% and 46% respectively. PBI-1393 increases also IL-2 and IFN-gamma mRNA expression as shown by RT-PCR. The physiological relevance of IL-2 and IFN-gamma gene modulation by PBI-1393 is illustrated by the advantageous increase of T cell proliferation (39+/-0.3% above control) and human CTL response against prostate (PC-3) cancer cells (42+/-0.03%). The enhancement of human T cell proliferation and CTL activation by PBI-1393 demonstrates that this compound potentiates the immune response and in this regard, it could be used as an alternative approach to IL-2 and/or IFN-gamma therapy against cancer.
Collapse
Affiliation(s)
- Mustapha Allam
- ProMetic BioSciences Inc., 500 Cartier Blvd. West, Suite 150, Laval, Quebec, Canada H7V 5B7.
| | | | | | | | | |
Collapse
|
15
|
|
16
|
Chandrasekhar S, Latour S, Wuest JD, Zacharie B. Allylstannanes. Synthesis, structure, and reactions of 2-methylene-1,3-propanediylbis[trimethylstannane] and -[triphenylstannane]. J Org Chem 2002. [DOI: 10.1021/jo00169a042] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
|
18
|
|
19
|
|
20
|
|
21
|
|
22
|
Sauve G, Le Berre N, Zacharie B. Novel modifications of peptides: simple syntheses of difunctionalized enamines, enol ethers, and thioenol ethers from carboxylic acids via acylimidazole and enol phosphate intermediates. J Org Chem 2002. [DOI: 10.1021/jo00297a008] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Zacharie B, Moreau N, Dockendorff C. A mild procedure for the reduction of pyridine N-oxides to piperidines using ammonium formate. J Org Chem 2001; 66:5264-5. [PMID: 11463286 DOI: 10.1021/jo015649g] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- B Zacharie
- BioChem Pharma Inc., 275 Armand-Frappier Boulevard, Laval, Quebec, Canada.
| | | | | |
Collapse
|
24
|
Abstract
beta-Glucans are polysaccharides that act as nonspecific immune system stimulants. However, many beta-Glucans are sparingly soluble in water. This work describes an oxidative procedure, which solubilizes the beta-Glucan from Saccharomyces cerevisiae and maintains its immunostimulatory properties. Furthermore, the carboxylates at the site of oxidation allow for the conjugation of small molecule immunostimulants. Both the parent oxidized beta-glucan and its conjugates with O-beta-alanyl-5-[6-(N,N'-dimethylamino)purin-9-yl]pentanol stimulate cytotoxic T-lymphocytes (CTLs), B cells and macrophages. In addition, they both stimulate natural killer (NK) cells, a property which the small molecule purine does not possess.
Collapse
Affiliation(s)
- G G Cross
- National Research Council, 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
| | | | | | | | | | | |
Collapse
|
25
|
Abstract
Two series of 1,3-dioxolanes and 1,3-oxathiolane nucleosides containing N-9-oxypurine were synthesized as potential antiviral agents. These compounds were prepared by reacting the sugar moieties with iodo- or bromotrimethylsilane, followed by treatment with a mixture of sodium hydride and the desired N-hydroxy purine base. The preparation of these N-hydroxybases was also described. No significant antiviral activity was observed against HIV, HBV, HSV-1, HSV-2, or HCMV.
Collapse
|
26
|
Kadhim S, Penney C, Lagraoui M, Heibein J, Attardo G, Zacharie B, Connolly T, Gagnon L. Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide. Int J Immunopharmacol 2000; 22:659-71. [PMID: 10884587 DOI: 10.1016/s0192-0561(00)00028-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
N,N-dimethylaminopurine pentoxycarbonyl D-arginine (BCH-1393) is a novel low molecular weight synthetic immunomodulator that has been shown to significantly stimulate cytotoxic T-lymphocyte responses both in vitro and in vivo (Zacharie B, Gagnon L, Attardo G, Connolly TP, St-Denis Y, Penney CL. Synthesis and activity of 6-substituted purine linker amine immunostimulants. J. Med. Chem. 1997;40:2883-94). Prompted by this evidence, we extended evaluation of BCH-1393 for anticancer activity in syngeneic mouse experimental tumor models. Consistent with previous findings, in vitro assessment of BCH-1393 activity demonstrated a significant increase in the CTL responses in the range of 10(-9)-10(-5) M. Treatment of mice with four consecutive daily intraperitoneal injections at 25 and 50 mg/kg resulted in a significant increase of the relative percentage of blood CD4+, CD8+, NK and monocyte subsets without any evidence of toxicity. In vivo anti-tumor activity of BCH-1393 was evaluated, either alone or in combination with subtherapeutic doses of cyclophosphamide (Cy), against weakly immunogenic mouse breast carcinoma DA-3 and strongly immunogenic colon adenocarcinoma MC38. Daily intraperitoneal injection of BCH-1393 at 50 mg/kg alone was well tolerated but produced a relatively weak anti-tumor effect in both tumor models. However, a significant inhibition of tumor outgrowth and suppression of established tumor growth was observed when BCH-1393 was administered in combination with subtherapeutic doses of Cy. Combination treatment of 50 mg/kg BCH-1393 with 100 mg/kg Cy (given as single intravenous bolus injection) starting 2 days prior to DA-3 tumor cell inoculation prevented tumor outgrowth in 70-80% of treated mice. In the remaining 20-30% of mice that had developed tumors, a nearly complete (90%) tumor growth inhibition was observed at days 22-24 post tumor implant. In the MC38 tumor model, combination treatment of established tumors with BCH-1393 and Cy (CTX) at 50 mg/kg resulted in a significant delay in tumor growth compared to CTX treatment alone. The observed concomitant anti-tumor activity of BCH-1393 with cyclophosphamide warrants further investigation of this immunomodulator as an adjunctive treatment of cancer.
Collapse
MESH Headings
- Adjuvants, Immunologic/pharmacology
- Adjuvants, Immunologic/therapeutic use
- Animals
- Antineoplastic Combined Chemotherapy Protocols/pharmacology
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Arginine/analogs & derivatives
- Arginine/pharmacology
- Arginine/therapeutic use
- CD4-Positive T-Lymphocytes/drug effects
- Colonic Neoplasms/drug therapy
- Colonic Neoplasms/immunology
- Cyclophosphamide/pharmacology
- Cyclophosphamide/therapeutic use
- Cytotoxicity Tests, Immunologic
- Drug Evaluation, Preclinical
- Drug Synergism
- Female
- Immunophenotyping
- Immunosuppressive Agents/pharmacology
- Immunosuppressive Agents/therapeutic use
- Killer Cells, Natural/drug effects
- Mammary Neoplasms, Experimental/drug therapy
- Mammary Neoplasms, Experimental/immunology
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Monocytes/drug effects
- Purines/pharmacology
- Purines/therapeutic use
- T-Lymphocytes, Cytotoxic/drug effects
- T-Lymphocytes, Cytotoxic/immunology
- Time Factors
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- S Kadhim
- BiochemPharma Inc., Que., Laval, Canada
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
The tetrapeptide I (D-lysine-L-asparaginyl-L-prolyl-L-tyrosine or D-LysAsnProTyr), and analogue sequences, were synthesized and evaluated for the ability to stimulate immune cell subsets. These sequences were selected based on their perceived ability to readily adopt a beta-turn structure. In vitro immunological assays revealed a robust stimulation of mitogen activated B-cell proliferation and a modest to significant stimulation of cytotoxic T lymphocytes (CTLs). Further, this in vitro stimulation of B-cells was accompanied by an in vivo expansion of B-cells in C57BL/6 mice, as demonstrated by immunophenotyping experiments. Interestingly, a conformational analysis of the low energy conformers of I and the endogenous B-cell stimulant bursin (LysHisGlyNH2) shows that these molecules can be superimposed. However, I displayed significantly enhanced physiological stability. For a number of reasons, I may be a particularly useful vaccine adjuvant.
Collapse
Affiliation(s)
- L Gagnon
- BioChem. Pharma Inc., 275 Armand-Frappier Blvd., Laval, Canada
| | | | | | | | | |
Collapse
|
28
|
Nguyen-Ba N, Lee N, Chan L, Zacharie B. Synthesis of N-1-oxypyrimidine 1,3-dioxolane and 1,3-oxathiolane nucleosides. Chem Commun (Camb) 2000. [DOI: 10.1039/b006600l] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
29
|
Zacharie B, Lagraoui M, Dimarco M, Penney CL, Gagnon L. Thioamides: synthesis, stability, and immunological activities of thioanalogues of Imreg. Preparation of new thioacylating agents using fluorobenzimidazolone derivatives. J Med Chem 1999; 42:2046-52. [PMID: 10354413 DOI: 10.1021/jm9900467] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Imreg (Tyr1-Gly2-Gly3) is a well-known immunostimulant. However, it possesses a short half-life. Stabilized analogues of Imreg were prepared by a regioselective insertion in which peptide bonds at position 1,2 or 2,3 were replaced by thioamide linkages. This was achieved by using new thioacylating agents based on thioacyl-fluoro-N-benzimidazolone. The synthesis and properties of these reagents are described herein. This peptide modification enhanced significantly the half-life of the thioanalogues relative to Imreg in blood. The thioanalogues and Imreg were tested in vitro in T and B cell proliferation assays and for their ability to stimulate cytotoxic T-lymphocytes (CTLs). Only thiotyrosyl glycyl glycine 11 displayed some activity as evidenced by a weak stimulation of CTLs. On the basis of this activity and the increased stability, an in vivo immunological evaluation was undertaken. Immunophenotyping of 11 revealed a significant increase in activated CTL and NK cell populations in the spleen. This expansion was also accompanied by a significant stimulation of NK cells and the B cell proliferative response. Thioanalogues of Imreg were generally nontoxic, as exemplified by 11. The latter is a promising immunostimulant which may be targeted for cancer and viral infections, where CTLs and NK cells play an important role, or as a vaccine adjuvant where stimulation of antibody-producing B cells is important.
Collapse
Affiliation(s)
- B Zacharie
- BioChem Pharma Inc., 275 Armand-Frappier Blvd., Laval, Quebec, Canada, H7V 4A7
| | | | | | | | | |
Collapse
|
30
|
Nguyen-Ba N, Brown WL, Chan L, Lee N, Brasili L, Lafleur D, Zacharie B. Synthesis and anti-HIV activity of 1,3-dithiolane nucleosides. Chem Commun (Camb) 1999. [DOI: 10.1039/a901927h] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
31
|
Abbott SD, Gagnon L, Lagraoui M, Kadhim S, Attardo G, Zacharie B, Penney CL. Synthesis and activity of dipeptides, linked to targeting ligands, as specific NK cell enhancers. J Med Chem 1998; 41:1909-26. [PMID: 9599240 DOI: 10.1021/jm970734v] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Water soluble analogues of the lipophilic immunostimulant, octadecyl D-alanyl-L-glutamine, BCH-527, were synthesized and evaluated for the ability to stimulate natural killer (NK) cells. One of these compounds in which the octadecyl chain of BCH-527 was replaced with a shorter chain alcohol, 6-(D-alanyl-L-glutaminylamino)hexan-1-ol, 9, displayed an in vitro stimulation of NK cells comparable to that of interleukin 2 (IL 2). However, when the hydroxyl of 9 was linked to L-fucose to yield 1-beta-[6-(D-alanyl-L-glutaminylamino)hex-1-yl]-L- fucopyranose (BCH-2537, 1), the observed stimulation of NK cells was greater than that observed with IL 2. Further evaluation of these compounds revealed that the improved in vitro activity of BCH-2537 was more pronounced in vivo. That is, while both compounds significantly increased splenic NK cells, only BCH-2537 significantly increased the activity of these cells in vivo. In terms of a structure-activity relationship, NK cell activity was sensitive to minor structural modifications. It was influenced by conservative substitutions within the dipeptide, the length of the hydrocarbon chain, and the functionality at the end of the chain. No other compound enhanced NK cell activity to the extent exhibited by BCH-2537, although a few were equipotent to 9.
Collapse
Affiliation(s)
- S D Abbott
- Department of Medicinal Chemistry, BioChem Thérapeutique Inc., 275 Boulevard Armand-Frappier, Laval, Québec, H7V 4A7, Canada
| | | | | | | | | | | | | |
Collapse
|
32
|
Nguyen-Ba N, Brown W, Lee N, Zacharie B. Short Synthesis of 2,4-Disubstituted 1,3-Oxathiolane and 1,3-Dithiolane Cytosine Nucleosides: Facile Introduction of a 4-Benzoate Group Using Benzoyl Peroxide. SYNTHESIS-STUTTGART 1998. [DOI: 10.1055/s-1998-2065] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
33
|
Zacharie B, Gagnon L, Attardo G, Connolly TP, St-Denis Y, Penney CL. Synthesis and activity of 6-substituted purine linker amino acid immunostimulants. J Med Chem 1997; 40:2883-94. [PMID: 9288170 DOI: 10.1021/jm960844m] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
A series of 6-substituted purinyl alkoxycarbonyl amino acids were synthesized and evaluated for their ability to stimulate cytotoxic T lymphocytes (CTLs) and the mixed lymphocyte reaction (MLR). A few of these compounds, in particular [[5-[6-(N,N-dimethylamino)purin-9-yl]pentoxy]-carbonyl]D-arginine (BCH-1393, 4a), displayed an in vitro stimulation of CTLs comparable to interleukin 2 (IL 2). BCH-1393 increased the CTL response between 10(-9) M and 10(-5) M. Further, this potent in vitro activity was reflected as a significant increase in CTL cell number in vivo. However, immunophenotyping of some of the other equipotent compounds did not reveal a parallel relative increase in CTLs in vivo. It was difficult to formulate a rigorous structure-activity relationship based on in vitro CTL activity. Nevertheless, the activity was dependent upon the nature of the 6-substituent on the purine, the type and stereochemistry of the amino acid, and the distance and spatial freedom between the purine and amino acid as defined by the length and rigidity of the linker. These compounds were generally nontoxic, as exemplified by BCH-1393. BCH-1393 is a promising immunostimulant which may be targeted for those disease states which require an increased CTL or TH1 type response.
Collapse
Affiliation(s)
- B Zacharie
- Department of Medicinal Chemistry, BioChem Therapeutic Inc., Laval, Quebec
| | | | | | | | | | | |
Collapse
|
34
|
Mansour TS, Evans CA, Siddiqui MA, Charron M, Zacharie B, Nguyen-Ba N, Lee N, Korba B. Structure-Activity Relationship of Pyrimidine Heterosubstituted Nucleoside Analogues. ACTA ACUST UNITED AC 1997. [DOI: 10.1080/07328319708006122] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
35
|
Zacharie B, Connolly TP, Rej R, Attardo G, Penney CL. A short synthesis of 4-substituted 1-(hydroxyalkyl)-1H-pyrazolo[3,4-d]pyrimidines. Tetrahedron 1996. [DOI: 10.1016/0040-4020(95)01060-2] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
36
|
Zacharie B, Martel R, Sauve G, Belleau B. Chemoselective thioacylation of amino acids. Preparation of the four monothiothymopentin analogs and their biological activity. Bioorg Med Chem Lett 1993. [DOI: 10.1016/s0960-894x(01)81241-5] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
37
|
Humber DC, Jones MF, Payne JJ, Ramsay MV, Zacharie B, Jin H, Siddiqui A, Evans CA, Tse H, Mansour TS. Expeditious preparation of (−)-2′-deoxy-3′-thiacytidine (3TC). Tetrahedron Lett 1992. [DOI: 10.1016/s0040-4039(00)61330-8] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
38
|
Sauvé G, Le Berre N, Zacharie B. Carboxyl-modified amino acids and peptides: II) A convenient route for the synthesis of difunctionalized enamines from thioamides via thioiminium salts. Tetrahedron Lett 1988. [DOI: 10.1016/s0040-4039(00)86042-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Zacharie B, Wuest JD, Olivier MJ, Beauchamp AL. Structure of tetraphenylphosphonium triiodomercurate(II), [P(C6H5)4][HgI3]. Acta Crystallogr C 1985. [DOI: 10.1107/s0108270185003948] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|